Literature DB >> 12920242

Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue.

Georg E Steiner1, Ursula Stix, Alessandra Handisurya, Martin Willheim, Andrea Haitel, Franz Reithmayr, Doris Paikl, Rupert C Ecker, Kristian Hrachowitz, Gero Kramer, Chung Lee, Michael Marberger.   

Abstract

The aim of the study is to characterize the type of immune response in benign prostatic hyperplasia (BPH) tissue. BPH tissue-derived T cells (n = 10) were isolated, activated (PMA + ionomycin), and analyzed for intracellular reactivity with anti-IFN-gamma and IL-2, -4, -5, -6, -10, and -13, as well as TNF-alpha and -beta by four-color flow cytometry. Lymphokine release was tested using Th1/Th2 cytokine bead arrays. The amount of IFN-gamma and IL-2, -4, -13, and TGF-beta mRNA expressed in normal prostate (n = 5) was compared with that in BPH tissue separated into segments with normal histology (n = 5), BPH histology with (n = 10) and without (n = 10) lymphocytic infiltration, and BPH nodules (n = 10). Expression of lymphokine receptors was analyzed by immunohistology, flow cytometry, and RT-PCR. We found that 28 +/- 18% of BPH T helper cells were IFN-gamma(+)/IL-4(-) Th1 cells, 10 +/- 2% were IFN-gamma(-)/IL-4(+) Th2, and 12 +/- 6% were IFN-gamma(+)/IL-4(+) Th0 cells. In relation, cytotoxic and double-negative BPH T lymphocytes showed a slight decrease in Th1 and Th0 in favor of Th2. In double-positive BPH T lymphocytes, the trend toward Th2 (35 +/- 15%) was significant (Th1: 12 +/- 7%; Th0: 5 +/- 4%). Lymphokine release upon stimulation was found in the case of IL-2, IL-5, IFN-gamma, and TNF-alpha > 4 microg; of IL-4 > 2 microg; and of IL-10 > 1 microg/ml. Expression of lymphokine mRNA in tissue was increased (2- to 10-fold) in infiltrated BPH specimens with and without BPH histology. The infiltrated BPH specimens with normal histology differed from those with BPH histology, most evident by the significant decrease in IFN-gamma and the increase in TGF-beta mRNA expression. Infiltrated BPH specimens with BPH histology expressed significantly more IFN-gamma (5-fold), IL-2 (10-fold), and IL-13 (2.8-fold) when compared with noninfiltrated BPH specimens. BPH nodules, however, showed the highest level of expression of IL-4 and IL-13, with only intermediate levels of IFN-gamma and very low levels of IL-2 mRNA. Immune response in histologically less transformed BPH specimens is primarily of type 1, whereas in chronically infiltrated nodular BPH and especially within BPH nodules, it is predominantly of type 0 or type 2.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920242     DOI: 10.1097/01.lab.0000081388.40145.65

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  69 in total

1.  Advances in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: highlights from the 21st European association of urology congress, april 5-8, 2006, paris, france.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2006

2.  [Chronic inflammation as promotor and treatment target in benign prostate hyperplasia (BPH) and in prostate cancer].

Authors:  G Kramer; D Mitteregger; A Maj-Hes; S Sevchenco; W Brozek
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

3.  Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.

Authors:  Pradeep Tyagi; Saundra S Motley; Tatsuki Koyama; Mahendra Kashyap; Jeffrey Gingrich; Naoki Yoshimura; Jay H Fowke
Journal:  Prostate       Date:  2017-10-27       Impact factor: 4.104

Review 4.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

Review 5.  Benign prostatic hyperplasia: a new metabolic disease?

Authors:  L Vignozzi; G Rastrelli; G Corona; M Gacci; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

Review 6.  Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia.

Authors:  Vatsal Mehta; Chad M Vezina
Journal:  Differentiation       Date:  2011 Nov-Dec       Impact factor: 3.880

7.  Acute bacterial inflammation of the mouse prostate.

Authors:  Bayli J Boehm; Sara A Colopy; Travis J Jerde; Christopher J Loftus; Wade Bushman
Journal:  Prostate       Date:  2011-06-16       Impact factor: 4.104

8.  Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.

Authors:  Kazutoshi Fujita; Charles M Ewing; Robert H Getzenberg; J Kellogg Parsons; William B Isaacs; Christian P Pavlovich
Journal:  Prostate       Date:  2010-04-01       Impact factor: 4.104

9.  Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model.

Authors:  Mehrnaz Gharaee-Kermani; Jose A Rodriguez-Nieves; Rohit Mehra; Chad A Vezina; Aruna V Sarma; Jill A Macoska
Journal:  Prostate       Date:  2013-03-26       Impact factor: 4.104

10.  Etiopathogenesis of benign prostatic hypeprlasia.

Authors:  Jie Tang; Jingchun Yang
Journal:  Indian J Urol       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.